Safety evaluation of a food enzyme containing leucyl aminopeptidase, oryzin and aspergillopepsin I from the non‐genetically modified Aspergillus sp. strain AE‐PR Authors: EFSA Panel on Food Enzymes (FEZ), Holger Zorn, José Manuel Barat Baviera, Claudia Bolognesi, Francesco Catania, Gabriele Gadermaier, Ralf Greiner, Baltasar Mayo, Alicja Mortensen, Yrjö Henrik Roos, Marize L. M. Solano, Henk Van Loveren, Laurence Vernis, Simone Lunardi, Magdalena Andryszkiewicz, Daniele Cavanna, Natalia Kovalkovicova, Yi Liu Published: 2026 ABSTRACT AbstractThe food enzyme containing leucyl aminopeptidase (EC 3.4.11.1), oryzin (EC 3.4.21.63) and aspergillopepsin I (EC 3.4.23.18) activities is produced with the non‐genetically modified Aspergillus sp. strain AE‐PR by Amano Enzyme Inc. The food enzyme was considered free from viable cells of the production organism. It is intended to be used in 15 food manufacturing processes. Since residual amounts of food enzyme‐total organic solids (TOS) are removed in two processes, dietary exposure was calculated for the remaining 13 food manufacturing processes. It was estimated to be up to 0.203 mg TOS/kg body weight (bw) per day in European populations. Genotoxicity tests did not indicate a safety concern. The systemic toxicity was assessed by means of a repeated dose 90‐day oral toxicity study in rats. The Panel identified a no observed adverse effect level of 1898 mg TOS/kg bw per day, the highest dose tested, which when compared with the estimated dietary exposure, resulted in a margin of exposure of at least 9350. A search for the homology of the three amino acid sequences to known allergens was made and matches with 2 food, 22 respiratory, 3 contact and 1 injected allergens were found. The Panel considered that a risk of allergic reactions upon dietary exposure to this food enzyme cannot be excluded. Based on the data provided, the Panel concluded that this food enzyme does not give rise to safety concerns, under the intended conditions of use. INTRODUCTION Article 3 of the Regulation (EC) No 1332/2008 1 provides definition for ‘food enzyme’ and ‘food enzyme preparation’. ‘Food enzyme’ means a product obtained from plants, animals or microorganisms or products thereof including a product obtained by a fermentation process using microorganisms: (i) containing one or more enzymes capable of catalysing a specific biochemical reaction; and (ii) added to food for a technological purpose at any stage of the manufacturing, processing, preparation, treatment, packaging, transport or storage of foods. ‘Food enzyme preparation’ means a formulation consisting of one or more food enzymes in which substances such as food additives and/or other food ingredients are incorporated to facilitate their storage, sale, standardisation, dilution or dissolution. Before January 2009, food enzymes other than those used as food additives were not regulated or were regulated as processing aids under the legislation of the Member States. On 20 January 2009, Regulation (EC) No 1332/2008 on food enzymes came into force. This Regulation applies to enzymes that are added to food to perform a technological function in the manufacture, processing, preparation, treatment, packaging, transport or storage of such food, including enzymes used as processing aids. Regulation (EC) No 1331/2008 2 established the European Union (EU) procedures for the safety assessment and the authorisation procedure of food additives, food enzymes and food flavourings. The use of a food enzyme shall be authorised only if it is demonstrated that: it does not pose a safety concern to the health of the consumer at the level of use proposed;there is a reasonable technological need;its use does not mislead the consumer. it does not pose a safety concern to the health of the consumer at the level of use proposed; it does not pose a safety concern to the health of the consumer at the level of use proposed; there is a reasonable technological need; there is a reasonable technological need; its use does not mislead the consumer. its use does not mislead the consumer. All food enzymes currently on the EU market and intended to remain on that market, as well as all new food enzymes, shall be subjected to a safety evaluation by the European Food Safety Authority (EFSA) and approval via an EU Community list. Background and Terms of Reference as provided by the requestor Background as provided by the European Commission Only food enzymes included in the European Union (EU) Community list may be placed on the market as such and used in foods, in accordance with the specifications and conditions of use provided for in Article 7(2) of Regulation (EC) No 1332/2008 on food enzymes. Five applications have been introduced by the Association of Manufacturers and Formulators of Enzyme Products (AMFEP) for the authorisation of the food enzyme consisting of Protease, Leucyl amino‐peptidase, Oryzin and Aspergillopepsin I from Aspergillus oryzae and the companies “BENEO‐Palatinit GmbH” for the authorisation of the food enzyme Isomaltulose synthase from Protaminobacter rubrum (strain Z12A), “Nagase (Europa) GmbH” for the authorisation of the food enzyme Chitinase from a genetically modified strain of Streptomyces violaceoruber (strain pChi), “Clasado Ingredients Ltd.” for the authorisation of the food enzyme Beta‐galactosidase from a genetically modified strain of Escherichia coli (strain BglA MCB3) and “Meiji Seika Pharma Co., Ltd” for the authorisation of the food enzyme consisting of Aspergillopepsin I and II from Aspergillus niger var. macrosporus (strain DBD‐0406). Following the requirements of Article 12.1 of Regulation (EC) No 234/2011 3 implementing Regulation (EC) No 1331/2008, the Commission has verified that the five applications fall within the scope of the food enzyme Regulation and contain all the elements required under Chapter II of that Regulation. Terms of Reference The European Commission requests the European Food Safety Authority to carry out the safety assessments on the food enzymes Protease, Leucyl amino‐peptidase, Oryzin and Aspergillopepsin I from Aspergillus oryzae and the companies “BENEO‐Palatinit GmbH” for the authorisation of the food enzyme Isomaltulose synthase from Protaminobacter rubrum (strain Z12A), “Nagase (Europa) GmbH” for the authorisation of the food enzyme Chitinase from a genetically modified strain of Streptomyces violaceoruber (strain pChi), “Clasado Ingredients Ltd.” for the authorisation of the food enzyme Beta‐galactosidase from a genetically modified strain of Escherichia coli (strain BglA MCB3) and “Meiji Seika Pharma Co., Ltd” for the authorisation of the food enzyme consisting of Aspergillopepsin I and II from Aspergillus niger var. macrosporus (strain DBD‐0406) in accordance with Article 17.3 of Regulation (EC) No 1332/2008 on food enzymes. Interpretation of the Terms of Reference The present scientific opinion addresses the European Commission's request to carry out the safety assessment of food enzyme Protease, Leucyl aminopeptidase, Oryzin and Aspergillopepsin I from A. oryzae submitted by AMFEP. The application was submitted initially as a joint dossier 4 and identified as the EFSA‐Q‐2015‐00619. During a meeting between EFSA, the European Commission and the Association of Manufacturers and Formulators of Enzyme Products (AMFEP), 5 it was agreed that joint dossiers will be split into individual data packages. The current opinion addresses one data package originating from the former joint dossier. This data package is identified as EFSA‐Q‐2023‐00220 and concerns a food enzyme containing leucyl aminopeptidase, oryzin and aspergillopepsin I produced from the non‐genetically modified A. oryzae strain AE‐PR and submitted by Amano Enzyme Inc. Recent data identified the production microorganism as Aspergillus sp. (Section 3.1). Therefore, this name will be used in this opinion instead of A. oryzae. DATA AND METHODOLOGIES Data The applicant has submitted a dossier in support of the application for authorisation of the food enzyme containing leucyl aminopeptidase, oryzin and aspergillopepsin I produced from the non‐genetically modified A. oryzae strain AE‐PR. Additional information was requested from the applicant during the assessment process on 22 January 2024 and received on 29 May 2025 (see ‘Documentation provided to EFSA’). Additional information was also spontaneously submitted by the applicant on 28 December 2023. Methodologies The assessment was conducted in line with the principles described in the EFSA ‘Guidance on transparency in the scientific aspects of risk assessment’ (EFSA, 2009a) and following the relevant guidance documents of the EFSA Scientific Committee. The ‘Guidance on the submission of a dossier on food enzymes for safety evaluation’ (EFSA, 2009b) as well as the ‘Statement on characterisation of microorganisms used for the production of food enzymes’ (EFSA CEP Panel, 2019) have been followed for the evaluation of the application. Additional information was requested in accordance with the updated ‘Scientific Guidance for the submission of dossiers on food enzymes’ (EFSA CEP Panel, 2021) and the guidance on the ‘Food manufacturing processes and technical data used in the exposure assessment of food enzymes’ (EFSA CEP Panel, 2023). ASSESSMENT The food enzyme under application contains three declared activities:IUBMB nomenclatureLeucyl aminopeptidaseSystematic name–SynonymsCytosol aminopeptidase; leucine aminopeptidaseIUBMB NoEC 3.4.11.1CAS No9001‐61‐0EINECS No232‐618‐3 IUBMB nomenclatureLeucyl aminopeptidaseSystematic name–SynonymsCytosol aminopeptidase; leucine aminopeptidaseIUBMB NoEC 3.4.11.1CAS No9001‐61‐0EINECS No232‐618‐3 Leucyl aminopeptidases catalyse the hydrolysis of the peptide bonds of N‐terminal amino acid residues of proteins or peptides with a preference for leucine residues, resulting in the release of free amino acids.IUBMB nomenclatureOryzinSystematic name–SynonymsAspergillopeptidase B; aspergillopepsin B; aspergillopepsin FIUBMB NoEC. 3.4.21.63CAS No9074‐07‐1EINECS No232‐977‐6 IUBMB nomenclatureOryzinSystematic name–SynonymsAspergillopeptidase B; aspergillopepsin B; aspergillopepsin FIUBMB NoEC. 3.4.21.63CAS No9074‐07‐1EINECS No232‐977‐6 Oryzins catalyse the hydrolysis of proteins with broad specificity, resulting in the generation of peptides and free amino acids.IUBMB nomenclatureAspergillopepsin ISystematic name–Synonyms Aspergillus aspartic proteinase; carboxyl proteinase; pepsin‐type aspartic proteinaseIUBMB NoEC 3.4.23.18CAS No9025‐49‐4EINECS No232‐796‐2 IUBMB nomenclatureAspergillopepsin ISystematic name–Synonyms Aspergillus aspartic proteinase; carboxyl proteinase; pepsin‐type aspartic proteinaseIUBMB NoEC 3.4.23.18CAS No9025‐49‐4EINECS No232‐796‐2 Aspergillopepsins I are aspartic endopeptidases that catalyse the hydrolysis of peptide bonds in proteins with broad specificity, favouring hydrophobic residues in P1 and P1', but also accepting Lys in P1, resulting in the generation of peptides and free amino acids. The food enzyme under assessment is intended to be used in 15 food manufacturing processes as defined in the EFSA guidance (EFSA CEP Panel, 2023): processing of dairy products for the production of (1) flavouring preparations from dairy products and (2) modified milk proteins; (3) processing of eggs and egg products; processing of meat and fish products for the production of (4) modified meat and fish products and (5) protein hydrolysates from meat and fish proteins; processing of cereals and other grains for the production of (6) baked products, (7) cereal‐based products other than baked, (8) brewed products and (9) distilled alcohol; processing of plant‐ and fungal‐derived products for the production of (10) edible oils from plant and algae, (11) tea and other herbal and fruit infusions and (12) plant extracts, (13) plant‐based analogues of milk and milk products and (14) protein hydrolysates from plants and fungi; (15) processing of yeast and yeast products. Source of the food enzyme The food enzyme containing leucyl aminopeptidase, oryzin and aspergillopepsin I is produced with the non‐genetically modified filamentous fungus strain AE‐PR, which is deposited as A. oryzae at the National Institute of Technology and Evaluation (NITE) Biological Resource Center (Japan), with the deposition number ■■■■■. 6 The applicant declares that parental strain is ■■■■■, a strain used for production of the ■■■■■. The production strain AE‐PR was derived from the parental by classical mutagenesis. ■■■■■ 7 However, the results were insufficient to assign the production strain to either A. flavus or A. oryzae species. As a consequence, the production strain is referred to as Aspergillus sp. in this opinion. Production of the food enzyme The food enzyme is manufactured according to the Food Hygiene Regulation (EC) No 852/2004, 8 with food safety procedures based on Hazard Analysis and Critical Control Points and in accordance with Good Manufacturing Practice. 9 The production strain is grown as a pure culture using a typical industrial medium in a solid‐ state fermentation system with conventional process controls in place. After completion of the fermentation, the enzyme is extracted with ■■■■■ and then the solid biomass is removed from the suspension by filtration. The filtrate containing the enzyme is further purified and concentrated, including an ultrafiltration step in which enzyme protein is retained, while most of the low molecular mass material passes the filtration membrane and is discarded. 10 The applicant provided information on the identity of the substances used to control the fermentation and in the subsequent downstream processing of the food enzyme. 11 The Panel considered that sufficient information has been provided on the manufacturing process and the quality assurance system implemented by the applicant to exclude issues of concern. Characteristics of the food enzyme Properties of the food enzyme The leucyl aminopeptidase has ■■■■■ amino acids 12 and the molecular mass of the mature protein, calculated from its amino acid sequence, is ■■■■■ kDa. 13 The oryzin has ■■■■■ amino acids 14 and a calculated molecular mass of ■■■■■ kDa. 15 The aspergillopepsin I has ■■■■■ amino acids 16 and a calculated molecular mass of ■■■■■ kDa. 17 The food enzyme was analysed by size exclusion chromatography. 18 The chromatograms of three batches intended for commercialisation showed similar patterns. No other enzyme activities were reported. 19 The determination of leucyl peptidase activity is based on the hydrolysis of l‐leucyl‐glycyl‐glycine (reaction conditions: ■■■■■). The release of l‐leucine is measured by means of a colourimetric reaction detected at 570 nm. The enzyme activity is expressed in Units (U)/g. One U is defined as the amount of enzyme that releases 1 μmol of L‐leucine per minute under the assay conditions. 20 The determination of oryzin and aspergillopepsin I activities is based on the hydrolysis of casein (reaction conditions: ■■■■■) with the reaction carried out at ■■■■■ and ■■■■■, respectively. The release of soluble peptides is measured by means of a colourimetric reaction detected at 660 nm. The enzyme activity is expressed in proteinase Units (U)/g. One U is defined as the amount of enzyme that releases 1 μg of tyrosine equivalents per minute under the conditions of the assay. 21 , 22 The leucyl aminopeptidase activity of the food enzyme has a temperature optimum around 40–50°C (pH 7.0) and a pH optimum around 8.0 (37°C). The oryzin activity of the food enzyme has a temperature optimum around 50°C (pH 7.0) and a pH optimum around 6.0–9.0 (30°C). The aspergillopepsin I activity of the food enzyme has a temperature optimum around 50°C (pH 3.0) and a pH optimum around 6.0 (37°C). Thermostability was tested by pre‐incubation of the food enzyme for 60 min at different temperatures (pH 7.0 for leucyl aminopeptidase and oryzin activities and pH 3.0 for aspergillopepsin I activity). The leucyl aminopeptidase activity decreased above 37°C and showed around 23% residual activity at 70°C. The oryzin and aspergillopepsin I activities decreased above 30°C and showed no residual activity at 70°C. 23 Chemical parameters Data were provided for three batches of the food enzyme intended for commercialisation and two batches produced for the toxicological tests (Table 1). 24 The mean total organic solids (TOS) of the three batches intended for commercialisation was 92.2% and the mean enzyme activity/TOS ratios were 0.035 U/mg TOS for leucyl aminopeptidase, 105.7 U/mg TOS for oryzin and 89.9 U/mg TOS for aspergillopepsin I. TABLE 1Composition of the food enzyme.ParametersUnitBatches1234 a 5 b Leucyl aminopeptidase activity U/g c 27.035.634.439.733.4 Oryzin activity U/g d 94,300102,00097,000105,000100,000 Aspergillopepsin I activity U/g e 79,10084,00085,60080,80083,600 Protein %56.858.256.157.454.9 Ash %0.81.01.00.80.7 Water %7.16.66.93.54.4 Total organic solids (TOS) f %92.192.492.195.794.9 Leucyl aminopeptidase activity activity/TOS ratio U/mg TOS0.0290.0390.0370.0410.035 Oryzin activity/TOS ratio U/mg TOS102.4110105110105 Aspergillopepsin I activity/TOS ratio U/mg TOS85.990.992.984.488.1 a Batch used for the Ames test and in vitro mammalian cell micronucleus test. b Batch used for the repeated dose 90‐day oral toxicity study in rats. c Unit: U/g (see Section 3.3.1). d Unit: U/g (see Section 3.3.1). e Unit: U/g (see Section 3.3.1). f TOS calculated as 100% – % water – % ash. Composition of the food enzyme. Batch used for the Ames test and in vitro mammalian cell micronucleus test. Batch used for the repeated dose 90‐day oral toxicity study in rats. Unit: U/g (see Section 3.3.1). Unit: U/g (see Section 3.3.1). Unit: U/g (see Section 3.3.1). TOS calculated as 100% – % water – % ash. Purity The lead content in the three commercial batches and in the batches used for toxicological studies was below 5 mg/kg 25 which complies with the specification for lead as laid down in the general specifications for enzymes used in food processing (FAO/WHO, 2006). In addition, for arsenic, cadmium and mercury, the average concentrations determined in the batches intended for commercialisation were 0.076 mg/kg, 0.05 mg/kg and 0.002 mg/kg, respectively. 26 , 27 The Panel considered these concentrations as not of concern. The food enzyme complies with the microbiological criteria for total coliforms, E. coli and Salmonella, as laid down in the general specifications for enzymes used in food processing (FAO/WHO, 2006). In addition, Clostridium perfringens and coagulase positive Staphylococcus were examined in all batches intended for commercialisation and all were below the limit of detection of the method. 28 , 29 No antimicrobial activity was detected in any of the tested batches. 30 Strains of the Aspergillus species, in common with most filamentous fungi, have the capacity to produce a range of secondary metabolites (Frisvad et al., 2018). The presence of aflatoxins (B1, B2, G1, G2), ochratoxin A, sterigmatocystin, T‐2 toxin, HT‐2 toxin, deoxynivalenol and zearalenone was examined in all food enzyme batches and all were below the limit of quantification (LoQ) of the applied methods. 31 , 32 Adverse effects caused by the possible presence of other secondary metabolites are addressed by the toxicological examination of the food enzyme. The Panel considered that the information provided on the purity of the food enzyme was sufficient. Viable cells of the production strain The absence of viable cells of the production strain in the food enzyme was demonstrated in three independent batches analysed in triplicate. ■■■■■. No colonies were detected. A positive control was included. 33 Toxicological data A battery of toxicological tests including a bacterial reverse mutation test (Ames test), an in vitro mammalian cell micronucleus test and a repeated dose 90‐day oral toxicity study in rats has been provided. The batches 4 and 5 (Table 1) used in these studies have similar activity/TOS ratios to the three batches intended for commercialisation, and thus are considered suitable as test items. Genotoxicity Bacterial reverse mutation test A bacterial reverse mutation test (Ames test) was performed according to the Organisation for Economic Co‐operation and Development (OECD) Test Guideline 471 (OECD, 2020) and following Good Laboratory Practice (GLP). 34 Four strains of S. Typhimurium (TA98, TA100, TA1535 and TA1537) and E. coli WP2uvrA were used with or without metabolic activation (S9‐mix), applying the treat and plate method. The dose‐finding study and main experiments were carried out in triplicate. The dose‐finding study was carried out using seven concentrations of the food enzyme ranging from 20.5 to 5000 μg TOS/plate. Growth inhibition was observed at 800 μg TOS/plate and above in strain TA1535 without S9‐mix and at 5000 μg TOS/plate in strains TA100 and TA1535 with S9‐mix. Upon treatment with the food enzyme, there was no biologically relevant increase in the number of revertant colonies above the control values, in any strain tested, with or without S9‐mix. Based on these results, the main experiment was carried out using seven concentrations of the food enzyme of 19.5, 39, 78, 156, 313, 625 and 1250 μg TOS/plate in strain TA1535 without S9‐mix and six concentrations of the food enzyme of 156, 313, 625, 1250, 2500 and 5000 μg TOS/plate in the other four strains tested without S9‐mix and in all five strains tested with S9‐mix. Growth inhibition was observed at 313 μg TOS/plate and above in strain TA1535 without S9‐mix and at 5000 μg TOS/plate in strains TA100 and TA1535 with S9‐mix. Upon treatment with the food enzyme there was no biologically relevant increase in the number of revertant colonies above the control values, in any strain tested, with or without S9‐mix. The study was considered reliable without restrictions and the results of high relevance. The Panel concluded that the food enzyme containing leucyl aminopeptidase, oryzin and aspergillopepsin I did not induce gene mutations under the test conditions applied in this study. In vitro mammalian cell micronucleus test The in vitro mammalian cell micronucleus test was carried out according to the OECD Test Guideline 487 (OECD, 2023) and following GLP. 35 An experiment was performed with duplicate cultures of a human lymphoblastoid cell line (TK6). The cell cultures were treated with the food enzyme with or without metabolic activation (S9‐mix). Based on the results of a range finding study, cells were exposed to the food enzyme and scored for the frequency of bi‐nucleated cells with micronuclei (MNBN) at concentrations of 840, 1680 and 2620 μg TOS/mL in a short‐term treatment (3‐h exposure and 24‐h recovery period) without S9‐mix, at concentrations of 1680, 2920 and 3600 μg TOS/mL in a short‐term treatment (3‐h exposure and 24‐h recovery period) with S9‐mix and at concentrations of 156, 312 and 386 μg TOS/mL in a long‐term treatment (24‐h exposure without recovery period) without S9‐mix. In the short‐term treatment, cytotoxicity of 56% (based on the replication index) was observed at 2620 μg TOS/mL without S9‐mix and cytotoxicity of 51% was observed at 3600 μg TOS/mL with S9‐mix. In the long‐term treatment, cytotoxicity of 51% was observed at concentration of 386 μg TOS/mL. The frequency of MNBN was not statistically significantly different to the negative controls at all concentrations tested. The study was considered reliable without restrictions and the results of high relevance. The Panel concluded that the food enzyme containing leucyl aminopeptidase, oryzin and aspergillopepsin I did not induce an increase in the frequency of MNBN under the test conditions applied in this study. Repeated dose 90‐day oral toxicity study in rodents The repeated dose 90‐day oral toxicity study was performed under GLP and according to OECD Test Guideline 408 (OECD, 2018). 36 Groups of 10 male and 10 female Sprague–Dawley (Crl:CD(SD)) rats received the food enzyme by gavage in doses of 475, 949 or 1898 mg TOS/kg bw per day. Controls received the vehicle (water for injection). No mortality was observed. The feed consumption was statistically significantly decreased in week 5 of administration in mid‐dose males (−10%). The Panel considered the change as not toxicologically relevant, as it was only recorded at a single time interval, it was only observed in one sex, there was no dose–response relationship and there was no statistically significant change in the final feed consumption, body weight or the body weight gain. In the functional observations, a statistically significant decrease in rearing was observed in high‐dose females (−33%) in week 12 of administration, an increase in total value of motor activity (0–60 min) in high‐dose males (+48%), an increase in total value of motor activity (+40%) and motor activity at 20–30 min (+76%), at 30–40 min (+190%) and at 40–50 min intervals (+161%) in mid‐dose females. The Panel considered the changes as not toxicologically relevant, as they were only recorded at single time intervals (all parameters), they were only observed in one sex (rearing, motor activity at several intervals), there was no dose–response relationship (motor activity in females) and the changes were within the historical control values. Clinical chemistry investigations revealed a statistically significant increase in glucose in high‐dose males (+12%) and an increase in inorganic phosphorus concentration in high‐dose females (+23%). The Panel considered the changes as not toxicologically relevant, as they were only observed in one sex (both parameters) and the changes were within the historical control values. Statistically significant changes in hormone levels included a decrease in thyroid stimulating hormone (TSH) in high‐dose females (−38%). The Panel considered the change as not toxicologically relevant, as it was only observed in one sex, there were no changes in thyroid hormones, there were no histopathological changes in thyroid and pituitary glands and the change was within the historical control values. The water intake measured during the 24‐h urine collection was statistically significantly increased in mid‐ and high‐dose females (+31% both). Urinalysis revealed a statistically significant increase in urine volume (+6%) and a decrease in osmotic pressure (−25%) in high‐dose females. The Panel considered the changes as not toxicologically relevant, as they were only observed in one sex (all parameters), there was no dose–response relationship (water intake), there were no changes in other relevant parameters (electrolytes in blood), there were no histopathological changes in kidneys and the changes were within the historical control values. Statistically significant changes detected in organ weights were an increase in the absolute and in relative prostate weight in low‐, mid‐ and high‐dose males (+23%, +24% and +19% and +19%, +24% and +14%), an increase in the absolute and relative weights of the salivary gland in high‐dose males (+14% and +12%), an increase in the absolute weight of the salivary gland in high‐dose females (+11%) and a decrease in the relative thyroid weight in low‐dose males (−17%). The Panel considered the changes as not toxicologically relevant, as they were only observed in one sex (relative thyroid weight), there was no dose–response relationship (absolute and relative prostate weight, relative thyroid weight), there were no histopathological changes in prostate, salivary glands and thyroid gland and the changes were within the historical control values (prostate, salivary glands). The microscopic examination revealed minimal hyperplasia of the squamous cells in the limiting ridge in 2/10 mid‐dose males and in 5/10 high‐dose males, accompanied by inflammatory cell infiltration in the submucosa and eosinophilic globules in the neck mucus cells in the fundus of the stomach in 2/10 mid‐dose males (minimal severity) and in 3/10 high‐dose males (severity minimal in 2 and mild in 1). The Panel noted that squamous cell hyperplasia is relatively common in oral gavage studies when the test item has an irritating potential. The Panel viewed the hyperplasia of the squamous cells in the limiting ridge and eosinophilic globules in the neck mucus cells in the fundus as an adaptive response to the test item related irritation within the stomach, which was not adverse based on the low severity grades of the findings. The Panel also noted the absence of these changes in high‐dose females. No toxicologically relevant or other statistically significant differences from controls were reported. The Panel identified a no observed adverse effect level (NOAEL) of 1898 mg TOS/kg bw per day, the highest dose tested. Allergenicity The allergenicity assessment considered only the food enzyme and not additives, carriers or other excipients that may be used in the final formulation. The potential allergenicity of the food enzyme containing leucyl aminopeptidase, oryzin and aspergillopepsin I from Aspergillus sp. strain AE‐PR was assessed by comparing their amino acid sequences with those of known allergens as described in the EFSA GMO Scientific Opinion (EFSA GMO Panel, 2010). Using higher than 35% identity in a sliding window of 80 amino acids as the criterion, no match was found for leucyl aminopeptidase 37 ; matches with 2 food, 19 respiratory and 3 contact allergens were found for oryzin 38 ; and matches with three respiratory and one injected allergens were found for aspergillopepsin I 39 in the AllergenOnline database and the Allergen Database for Food Safety. 40 The matching food allergens were Bac s 1 (49.4%), a nattokinase from Bacillus subtilis and Cuc m 1 (36.8% sequence identity), a subtilisin‐like protease from melon (Cucumis melo). The matching respiratory allergens (41.2%–100% sequence identity) were serine proteases from different species: Aspergillus flavus, A. fumigatus, A. versicolor, A. niger, Rhodotorula mucilaginosa, Penicillium chrysogenum, P. oxalicum, P. citrinum, Alternaria alternata, Cochliobolus lunatus, Cladosporium cladosporioides, Fusarium proliferatum, Davidiella tassiana, Bacillus lentus, B. licheniformis, Rhizopus oryzae and pig (Sus scrofa). Among them is Asp o 13, an alkaline serine protease from A. oryzae which is identical to oryzin in the food enzyme under assessment. The matching contact allergens were Tri r 2 (60.0% sequence identity), a subtilisin‐like protease from the Athlete's foot fungus (Trichophyton rubrum) and subtilisin‐like proteases from T. benhamiae and T. schoenleinii (58.8% sequence identity). The matching injected allergen was Aed a 11 (40.7% sequence identity), a lysosomal aspartic protease from Yellow fever mosquito (Aedes aegypti). No reports on oral or respiratory sensitisation or elicitation reactions of the food enzyme under assessment have been published. 41 Bac s 1, the nattokinase from B. subtilis, has been identified as a food allergen. Few case reports of allergic reactions after consumption of natto have been reported (Inomata et al., 2012; Suzuki et al., 2023). Allergic reactions after consumption of melon have been reported (Hassan & Venkatesh, 2015; Neeharika & Sunkar, 2021). Concerning the matches with respiratory allergens which were all serine proteases, the Panel notes that several studies have shown that individuals respiratorily sensitised to a food enzyme are usually able to ingest the corresponding enzyme without acquiring clinical symptoms of food allergy (Armentia et al., 2009; Cullinan et al., 1997; Poulsen, 2004). No allergic reactions to oral ingestion of the contact allergens (alkaline proteases) from Trichophyton rubrum, T. benhamiae and T. schoenleinii, fungi residing on the skin, are expected. Aspartic proteases are associated with allergic reactions to insects, but allergic reactions after oral exposure have not been reported (Cantillo et al., 2017). The Panel considered that the results of the sequence homology search and the available literature indicate a risk of allergic reactions for natto and melon allergic individuals upon dietary exposure to the food enzyme under assessment. The production strain belongs to the Aspergillus genus, which is known to cause respiratory allergy (Kurup et al., 2000; Shen & Han, 1998; Vermani et al., 2015). Allergic reactions upon dietary exposure have been observed, but are rare (Xing et al., 2022). The biomass is removed during the production process; however, allergenic proteins of the production strain can be released into the culture medium from which the food enzyme is obtained. ■■■■■, products from ■■■■■ that may cause allergies or intolerances (listed in the Regulation (EU) No 1169/2011 42 ) are used as raw materials. During the fermentation process, these products will mostly be degraded and utilised by the production strain. Taken together, concerning the potential allergic reactions due to the production strain and the raw material in the culture medium, the Panel considered that residual amounts of allergenic proteins could be present in the food enzyme. Taking into account the level of dietary exposure (see Section 3.5), this would result in minute amounts in the final foods, from which allergic reactions are usually not expected. In conclusion, when used for the production of distilled alcohols, the Panel considered that a risk of allergic reactions upon dietary exposure can be excluded. For the remaining intended uses, the risk of allergic reactions upon dietary exposure to this food enzyme, particularly for natto and melon allergic individuals, cannot be excluded. However, the likelihood of such reactions will not exceed the risk of reactions after natto and melon consumption. Dietary exposure Intended use of the food enzyme The food enzyme is intended to be used in 15 food manufacturing processes at the actual use levels summarised in Table 2. TABLE 2Intended uses and recommended use levels of the food enzyme as provided by the applicant. 43 , 44 Food manufacturing process a Raw material (RM)Actual use level (mg TOS/kg RM) b Processing of dairy products Production of flavouring preparations from dairy products Dairy products 45 5.6 Production of modified milk proteins c Milk protein 28.2 Processing of eggs and egg productsEggs 5.6 Processing of meat and fish products Production of modified meat and fish products Raw meat and fish 5.6 Production of protein hydrolysates from meat and fish proteins Meat and fish materials 28.2 Processing of cereals and other grains Production of baked products Flour 5.6 Production of cereal‐based products other than baked Cereals 5.6 Production of brewed products Cereals 28.2 Production of distilled alcohol Cereals112.7Processing of plant‐ and fungal‐derived products Production of edible oils from plant and algae Algae oil1349.5 Production of tea and other herbal and fruit infusions Tea leaves, herbs, fruits 33.8 Production of plant extracts Plant materials 33.8 Production of plant‐based analogues of milk and milk products Cereals, legumes, oil seeds, nuts5.6Grain‐based drinks 46 11.3 Other products Production of protein hydrolysates from plants and fungi c Plant proteins 28.2 Processing of yeast and yeast productsYeast biomass 5.6 a The names have been harmonised by EFSA according to the ‘Food manufacturing processes and technical data used in the exposure assessment of food enzymes’ (EFSA CEP Panel, 2023). b The numbers in bold were used for calculation. c This food enzyme is not used in the production of protein hydrolysates for use in infant formulae. 47 Intended uses and recommended use levels of the food enzyme as provided by the applicant. 43 , 44 Production of flavouring preparations from dairy products Production of flavouring preparations from dairy products Production of modified milk proteins c Production of modified milk proteins c Production of modified meat and fish products Production of modified meat and fish products Production of protein hydrolysates from meat and fish proteins Production of protein hydrolysates from meat and fish proteins Production of baked products Production of baked products Production of cereal‐based products other than baked Production of cereal‐based products other than baked Production of brewed products Production of brewed products Production of distilled alcohol Production of distilled alcohol Production of edible oils from plant and algae Production of edible oils from plant and algae Production of tea and other herbal and fruit infusions Production of tea and other herbal and fruit infusions Production of plant extracts Production of plant extracts Production of plant‐based analogues of milk and milk products Production of plant‐based analogues of milk and milk products Production of protein hydrolysates from plants and fungi c Production of protein hydrolysates from plants and fungi c The names have been harmonised by EFSA according to the ‘Food manufacturing processes and technical data used in the exposure assessment of food enzymes’ (EFSA CEP Panel, 2023). The numbers in bold were used for calculation. This food enzyme is not used in the production of protein hydrolysates for use in infant formulae. 47 In the production of flavouring preparations from dairy products, the food enzyme is added to dairy products (e.g. cheese, cream, butter) 48 during the incubation 49 to enhance the sensory properties. 50 The food enzyme–TOS remain in these enzyme‐modified dairy ingredients. In the production of modified milk proteins, the food enzyme is added to milk proteins after the mixing with water 51 to improve solubility and taste. The food enzyme–TOS remain in the modified milk proteins. In the processing of eggs and egg products, the food enzyme is added to the whole liquid egg, to the egg white or to the egg yolk during the incubation 52 to enhance the sensory properties. The food enzyme–TOS remain in the final egg products. In the production of modified meat and fish products, the food enzyme is added to meat and fish during the mincing 53 to soften the meat. 54 The food enzyme–TOS remain in the final foods. In the production of hydrolysed proteins, the food enzyme is added to plant (e.g. legumes and cereals) and animal source materials (e.g. meat, fish) 55 to enhance the flavour of the resultant protein hydrolysates. The food enzyme–TOS remain in these hydrolysates. In the production of baked products and cereal‐based products other than baked, the food enzyme is added to flour during the preparation of the dough or batter 56 to weaken the gluten structure in the dough, thus reducing its rigidity. The food enzyme could be also added to cereals to enhance the flavour in situ. 57 , 58 The food enzyme–TOS remain in the final products. In the production of brewed products, the food enzyme is added to the grains during the mashing for beer production. 59 In the production of fermented beverages such as sake, it may be added during slurry mixing, liquefaction, saccharification or fermentation. 60 The hydrolysis of proteins releases free amino nitrogen for the growth of yeast during fermentation. The food enzyme–TOS remain in the brewed products. In the production of distilled alcohol, the food enzyme is added during the liquefaction and fermentation, and it may also be added during slurry mixing and saccharification. 61 The enzymatic treatment improves the yield and enhances the access of amylolytic enzymes to the starch granules, facilitating the hydrolysis of starch and non‐starch polysaccharides into fermentable sugars. The food enzyme–TOS are not carried over with the distilled alcohols (EFSA CEP Panel, 2023). In the production of edible oils from algae, the food enzyme is added to the crude algal oil during the degumming and deacidification 62 to catalyse the hydrolysis of cell wall proteins. The food enzyme–TOS are removed from the final processed oils by the refining processes (EFSA CEP Panel, 2023). In the processing of tea, herbal and fruit infusions, the food enzyme is added to tea leaves, herbs and fruit 63 to enhance the sensory properties of the infusions. 64 The food enzyme–TOS remain in the final products. In the processing of plant extracts, the food enzyme is added to plant materials (vanilla, rosemary, paprika) 65 to improve the sensory properties of the final food ingredients, 66 in which the food enzyme–TOS remain. In the production of plant‐based analogues of milk and milk products, the food enzyme is added to the plant‐based drinks 67 to increase the yield and to enhance the flavour. 68 The food enzyme–TOS remain in these plant‐based dairy alternatives. In the processing of yeast and yeast products, the food enzyme is added to the yeast biomass during the lysis or during the incubation 69 to intensify the savoury taste of the yeast extracts. 70 The food enzyme–TOS remain in the yeast products. Based on the data provided on thermostability (see Section 3.3.1) and the downstream processing within the respective food manufacturing processes, the Panel considered that the food enzyme is inactivated in most of the food manufacturing processes listed in Table 2 in which the food enzyme–TOS remain. However, it may remain in its active form in baked products, brewed products and hamburgers, depending on the heat treatment conditions. Dietary exposure estimation In accordance with the guidance document (EFSA CEP Panel, 2021), dietary exposure was calculated for the 13 food manufacturing processes where the food enzyme–TOS remain in the final foods. Chronic exposure to the food enzyme–TOS was calculated using the FEIM webtool 71 by combining the maximum recommended use level with individual consumption data (EFSA CEP Panel, 2021). The estimation involved selection of relevant food categories and application of technical conversion factors (EFSA CEP Panel, 2023). Table 3 provides an overview of the derived exposure estimates across all surveys. Detailed mean and 95th percentile exposure to the food enzyme–TOS per age class, country and survey, as well as contribution from each FoodEx category to the total dietary exposure are reported in Appendix A – Tables 1 and 2. For the present assessment, food consumption data were available from 51 dietary surveys (covering infants, toddlers, children, adolescents, adults and the elderly), carried out in 27 European countries (Appendix B). The highest dietary exposure was estimated to be 0.203 mg TOS/kg bw per day in children at the 95th percentile. TABLE 3Summary of the estimated dietary exposure to the food enzyme–TOS in six population groups.Population groupEstimated exposure (mg TOS/kg body weight per day)InfantsToddlersChildrenAdolescentsAdultsThe elderly Age range 4–11 months12–35 months3–9 years10–17 years18–64 years≥ 65 years Min–max mean (number of surveys)0.027–0.054 (14)0.043–0.073 (17)0.028–0.073 (21)0.012–0.038 (23)0.019–0.049 (23)0.012–0.030 (25) Min–max 95th percentile (number of surveys)0.071–0.113 (13)0.081–0.126 (16)0.053–0.203 (21)0.024–0.069 (22)0.047–0.157 (23)0.033–0.083 (24) Summary of the estimated dietary exposure to the food enzyme–TOS in six population groups. Uncertainty analysis In accordance with the guidance provided in the EFSA opinion related to uncertainties in dietary exposure assessment (EFSA, 2006), the following sources of uncertainties have been considered and are summarised in Table 4. TABLE 4Qualitative evaluation of the influence of uncertainties on the dietary exposure estimate.Sources of uncertaintiesDirection of impact Model input data Consumption data: different methodologies/representativeness/underreporting/misreporting/no portion size standard+/−Use of data from food consumption surveys of a few days to estimate long‐term (chronic) exposure for high percentiles (95th percentile)+Possible national differences in categorisation and classification of food+/− Model assumptions and factors Selection of broad FoodEx categories for the exposure assessment+Exposure to food enzyme–TOS always calculated based on the recommended maximum use level+For the production of plant‐based analogues of milk and milk products, the higher use level was chosen to be used in the calculation.+For yeast processing, although only yeast extract is produced, 72 the food categories chosen for calculation cover also those containing mannoproteins resulting from the treatment of yeast cell walls.+In the production of cereal‐based products other than baked, beans are excluded from the exposure calculation+/−Use of recipe fractions to disaggregate FoodEx categories+/−Use of technical factors in the exposure model+/− Exclusion of two processes from the exposure estimation: – production of distilled alcohol – production of edible oils from plant and algae − Note: +, uncertainty with potential to cause overestimation of exposure; –, uncertainty with potential to cause underestimation of exposure. Qualitative evaluation of the influence of uncertainties on the dietary exposure estimate. Exclusion of two processes from the exposure estimation: – production of distilled alcohol – production of edible oils from plant and algae Note: +, uncertainty with potential to cause overestimation of exposure; –, uncertainty with potential to cause underestimation of exposure. The conservative approach applied to estimate the dietary exposure to the food enzyme–TOS, in particular assumptions made on the occurrence and use levels of this specific food enzyme, is likely to have led to an overestimation of the exposure. The exclusion of two food manufacturing processes from the exposure estimation was based on > 99% of TOS removal. This is not expected to impact the overall estimate derived. Margin of exposure A comparison of the NOAEL (1898 mg TOS/kg bw per day) identified from the 90‐day rat study with the derived exposure estimates of 0.012–0.073 mg TOS/kg bw per day at the mean and from 0.024 to 0.203 mg TOS/kg bw per day at the 95th percentile resulted in a margin of exposure of at least 9350. CONCLUSIONS Based on the data provided and the derived margin of exposure, the Panel concluded that the food enzyme containing leucyl aminopeptidase, oryzin and aspergillopepsin I produced with the non‐genetically modified Aspergillus sp. strain AE‐PR does not give rise to safety concerns under the intended conditions of use. DOCUMENTATION AS PROVIDED TO EFSA Application for authorisation of Leucyl aminopeptidase, Oryzin, and Aspergillopepsin I from Aspergillus oryzae AE‐PR in accordance with Regulation (EC) No 1331/2008. March 2023. Submitted by Amano Enzyme Inc. Additional information. December 2023 and May 2025. Submitted by Amano Enzyme Inc. ABBREVIATIONS Association of Manufacturers and Formulators of Enzyme Products body weight Chemical Abstracts Service EFSA Panel on Food Contact Materials, Enzymes and Processing Aids European Inventory of Existing Commercial Chemical Substances Food and Agricultural Organization of the United Nations Good Laboratory Practice genetically modified microorganism genetically modified organism International Union of Biochemistry and Molecular Biology Joint FAO/WHO Expert Committee on Food Additives kiloDalton limit of detection bi‐nucleated cells with micronuclei margin of exposure no observed adverse effect level Organisation for Economic Co‐operation and Development total organic solids whole genome sequencing World Health Organization REQUESTOR European Commission QUESTION NUMBER EFSA‐Q‐2023‐00220 COPYRIGHT FOR NON‐EFSA CONTENT EFSA may include images or other content for which it does not hold copyright. In such cases, EFSA indicates the copyright holder and users should seek permission to reproduce the content from the original source. PANEL MEMBERS José Manuel Barat Baviera, Claudia Bolognesi, Francesco Catania, Gabriele Gadermaier, Ralf Greiner, Baltasar Mayo, Alicja Mortensen, Yrjö Henrik Roos, Marize de Lourdes Marzo Solano, Henk Van Loveren, Laurence Vernis, Holger Zorn NOTE The full opinion will be published in accordance with Article 12 of Regulation (EC) No 1331/2008 once the decision on confidentiality will be received from the European Commission. Supporting information APPENDIX A: Dietary exposure estimates to the food enzyme–TOS in details